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Objective:Diabetes is associated with a more aggressive form of atherosclerosis. Thrombospondin-1 (TSP-1), an extracellular
matrix protein, is an acute-phase reactant that induces vascular smooth muscle (VSMC) migration and proliferation in areas
of vascular injury and is also up-regulated in VSMCs exposed to hyperglycemia. This study tested the hypothesis that
hyperglycemia amplifies the expression of genes induced by TSP-1 in VSMCs.
Methods:Human aortic VSMCs were cultured in DulbeccoModified Eagle’s Medium (DMEM) supplemented with 10% fetal
bovine serum (FBS) and 1% antibiotics. Cells were used between passages three and five. VSMCswere preincubated inDMEM
containing 0.2% FBS with 5 mM glucose (normoglycemia), 25 mM glucose (hyperglycemia), 25 mM mannose (osmotic
control), TSP-1 (20g/mL), 25mMglucoseTSP-1 (20g/mL), or 25mMmannoseTSP-1 (20g/mL). Total RNA
was extracted. Microarray analysis was performed and analyzed by analysis of variance. P < .05 was considered significant.
Quantitative real-time polymerase chain reaction (rtPCR) was used to confirm selected up-regulated genes.
Results: Microarray analysis revealed: (1) hyperglycemia altered 30 genes; (2) TSP-1 altered 212 genes, of which 8 were
altered similarly to VSMCs exposed to 25 mM glucose; (3) TSP-1 up-regulated 10 genes associated with atherosclerosis
and 4 others with diabetic vascular disease; (4) hyperglycemia combined with TSP-1 altered expression of 2822 genes.
The three genes most up-regulated by TSP-1 in a normoglycemic environment were uridine 5=-diphosphoglucose
(UDP-glucose) dehydrogenase (UGDH, 127%), transforming growth factor -2 (TGF2, 116%), and hyaluronan
synthase 2 (HAS2, 113%). Further, TSP-1 altered the expression of genes in 13 canonical pathways; however, when
combined with hyperglycemia, 53 canonical pathways were affected.
Conclusion:Quantitative rtPCR confirmed that genes in several of these pathways for TSP-1 and hyperglycemia combined
with TSP-1 were up-regulated. These findings suggest that TSP-1 may be germane to the progression of atherosclerosis
and may have a large effect with concurrent hyperglycemia. (J Vasc Surg 2010;51:1238-47.)
Clinical Relevance: Diabetes is increasing rapidly in the United States. One of the characteristics of this disease is accelerated
atherosclerosis. Thrombospondin-1 (TSP-1) has been shown to be involved in atherosclerosis and up-regulated in the tissues
of diabetic patients and in animal models of diabetes. Among other actions, TSP-1 has been shown to increase DNA synthesis
in vascular smooth muscle cells; however, the specific genes increased have not been completely identified. Further, the
influence of hyperglycemia on TSP-1–induced gene expression has not been fully determined. The present study demonstrates
that TSP-1 causes the up-regulation of several genes involved in atherosclerosis and diabetes and that hyperglycemia has a
substantial effect on this process.Understanding the apparent complex interaction betweenhyperglycemia andTSP-1will help
identify therapeutic targets and aid in the development of anti-TSP-1 strategies to reduce vascular disease in diabetes.The incidence of type 2 diabetes, a major cause of
death, is dramatically increasing in the United States.1 The
cost of diabetes to our health care system is estimated to
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1238exceed $200 billion by the year 2020.1 Further, the mor-
tality rate ultimately associated with cardiovascular disease
in type 2 diabetes is approximately 65%.2
The most common cardiovascular complication of dia-
betes is atherosclerosis. Atherosclerosis is a complex process
involving vascular remodeling in response to vessel injury.
In early atherosclerosis, there are three distinct stages:
1. endothelial cell injury and dysfunction trigger medial
vascular smooth muscle cell (VSMC) proliferation and
migration across the internal elastic lamina to form the
neointima;
2. VSMC proliferation in the neointima3,4; and
3. VSMCs switch to a synthetic phenotype and produce
extracellular matrix, which further expands the neoin-
tima.3,5,6
Mounting evidence indicates that glycoproteins, such
as thrombospondin-1 (TSP-1), have an important role in
vascular remodeling by regulating the arterial response to
injury.3,5,6 TSP-1 is a matricellular glycoprotein that is not
a part of the arterial wall structure.7 TSP-1 is increased
JOURNAL OF VASCULAR SURGERY
Volume 51, Number 5 Maier et al 1239acutely in areas of arterial injury and is expressed in athero-
sclerotic plaque.8-12 The term “matricellular” refers to
matrix proteins with a modular structure that do not play a
part in vascular wall structural integrity. Rather, these pro-
teins influence vascular physiology by binding other
proteins of the extracellular matrix, cell-surface receptors,
proteases, and cytokines, thus allowing these proteins to
exert multiple effects on cells.8,13 This type of complex
interaction clarifies the mechanisms by which TSP-1 exerts
different effects on cells such as having both antiadhesive
and proadhesive properties.8
Findings that implicate the role of TSP-1 in the devel-
opment of vascular remodeling are that TSP-1 causes en-
dothelial dysfunction, stimulates VSMC proliferation and
migration, and is increased locally after acute arterial inj-
ury.12,14-18 Specifically, research has shown that TSP-1-
induced VSMC migration functionally appears to be impor-
tant in vascular remodeling.5,6 In vivo research demonstrated
that animals pretreated with antibodies to the carboxy termi-
nal domain of TSP-1 (the domain predominantly associated
with VSMC migration) had decreased vascular remodeling
and increased re-endothelialization after arterial balloon injury
Table I. Sequences of the primers used for quantitative
real-time polymerase chain reaction to confirm the
canonical pathways
Gene symbol Sequence (5=-3=)
18 s rRNA
Forward GTAACCCGTTGAACCCCATT
Reverse CCATCCAATCGGTAGTAGCG
TSP-1
Forward CTGCTCCAATGCCACAGTTC
Reverse GGAGCCCTCACATCGGTTG
TGF 2
Forward AGAGTGCCTGAACAACGGATT
Reverse CCATTCGCCTTCTGCTCTT
HAS2
Forward TCCAAAGAGTGTGGTTCCAA
Reverse GACAGGCTGAGGACGACTTT
HES1
Forward GGCTGGAGAGGCGGCTAA
Reverse GAGAGGTGGGTTGGGGAGTT
FOS
Forward AAAAGGAGAATCCGAAGGGAAA
Reverse GTCTGTCTCCGCTTGGAGTGTAT
UGDH
Forward GCCAGGACTAAAAGAAGTGGTAG
Reverse TGCACAATGCGTCTAGCACAA
NFAT5
Forward CACCGCTTGTCTGACTCATT
Reverse GCCCAAGTCCCTCTACTCG
PIK3CA
Forward CCTGATCTTCCTCGTGCTGCTC
Reverse ATGCCAATGGACAGTGTTCCTCTT
ROCK2
Forward TTGTTTTTCCTCAAAGCAGGA
Reverse CGCTGATCCGAGACCCT
SOS1
Forward CGAGCCCTTTTCACTCAAGCAA
Reverse CAGGAGGAGGGACAGGCACTTCcompared with controls.3Previous studies have shown that hyperglycemia in-
creases the expression of TSP-1 in VSMCs.16 Further,
TSP-1 is expressed in the arterial wall of animal models of
type 2 diabetes and in tissues from patients with diabe-
tes.17,18 Given that TSP-1 contributes to the development
of atherosclerosis, TSP-1 may be important in this compli-
cation of diabetes. The role TSP-1 has in this complication
of diabetes warrants further study.
The mechanisms of TSP-1–induced VSMC prolifera-
tion, VSMC migration, and atherosclerosis in type 2 diabe-
tes have not been well characterized. The goal of this
project was to examine the early molecular changes in
VSMCs associated with hyperglycemia and TSP-1. In the
present study, we hypothesized that hyperglycemia ampli-
fies the expression of genes induced by TSP-1 in VSMCs.
MATERIALS AND METHODS
Materials. Purified TSP-1 (derived from human plate-
lets) was obtained from Calbiochem (Gibbstown, NJ).
Glucose and mannose were obtained from Sigma (St.
Louis, Mo).
Cell culture. Human VSMCs and human growth me-
dia were purchased from Cell Applications (San Diego,
Calif). Growth media was supplemented with 1% vol/vol
antibiotics (penicillin, streptomycin, amphotericin B), from
Gibco BRL Life Technologies (Grand Island, NY). Sub-
confluent monolayers of cell passages three to five were
used for each experiment.
Microarray. All groups consisted of three separate
experiments, and the microarray was run in triplicate on
each sample. Human VSMCs were cultured in Dulbecco
Modified Eagle’s Medium (DMEM) supplemented with
0.2% fetal bovine serum (FBS) for 24 hours and were then
treated for an additional 6 hours with one of the following:
Table II. Genes are listed that were up-regulated by
thrombospondin-1 in vascular smooth muscle cells as
determined by microarraya
Gene symbol Increase, % Gene description Disease
UGDH 127.0 UDP-glucose dehydrogenase A
TGFB2 116.0 Transforming growth factor-2 A, D
HAS2 113.0 Hyaluronan synthase 2 A, D
SLC2A1 100.0 Solute carrier family 2
(facilitated glucose
transporter), member 1
A
TIMP3 76.0 Tissue inhibitor of
metalloproteinase 3
A
SMAD7 66.0 MAD homolog 7 (Drosophila) A
THBS1 65.6 Thrombospondin-1 A
Serpine1 43.9 Serine (or cysteine) peptidase
inhibitor, clade E, member 1
A
GART 43.0 Phosphoribosylglycineamide
formyl transferase
A
SRF 42.0 Serum response factor A, D
UDP-glucose, uridine 5=-diphosphoglucose.
aA standard cutoff of up-regulation by 30% was used. Genes are also
identified by their association with atherosclerosis (A) or diabetes (D).TSP-1 (20 g/mL), 5 mM glucose (normoglycemia,
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equivalent to 450 mg/dL), 25 mM mannose (osmotic
control, chosen because it has the identical molecular
weight as glucose thus identical osmolality).
Total RNA was isolated from cells with the RNAeasy
Mini Kit (Qiagen, Valencia, Calif). The quality and quan-
tity of RNA was assessed with the Agilent 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, Calif) using an RNA
6000 Nano Chip. The RNA integrity number for the RNA
samples ranged from 8.1 to 9.0. The total RNA was then
processed according to the Affymetrix GeneChip Whole
Transcript Human Gene 1.0 ST Array Sense Target Label-
ing Assay Manual (Affymetrix, Santa Clara, Calif), using
150 ng of total RNA as the starting material.
The fragmented and labeled complementary DNA
(cDNA) that was produced was added to the GeneChip
Human Gene 1.0 ST Gene Array and hybridized at 45°C
for 16 hours. After hybridization, the arrays were washed
in an Affymetrix Fluidics Station 450 using protocol
FS450_0007 and scanned with an Affymetrix GeneChip
Scanner 7G Plus. Raw images were converted to CEL files
in GeneChip Operating System (GCOS) software (Affyem-
trix). The experimental data have been deposited as a series
(accession # GSE17556) in the NCBI Gene Expression
Omnibus (https://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?accGSE17556).
Quantitative real-time polymerase chain reaction.
In a separate set of experiments, the same groups used for
the microarray analysis were treated for 6 hours and RNA
was extracted, as above. cDNA was prepared using the
QuantiTect Probe RT-PCR Kit (Qiagen, Valencia, Calif).
Quantitative real-time polymerase chain reaction (qrtPCR)
was performed using the Lightcycler 480 SYBR Green
Master I (Roche Applied Science, Indianapolis, Ind). The
reactions contained 1 L of sample and were run on a
Lightcycler 480 Real Time PCR machine (Roche Applied
Science), with melting temperature set at 95°C and anneal-
ing temperature of 62°C for 50 cycles. No template con-
trols and melting curves were run for each primer. Primer sets
were obtained from the Quantitative PCR Primer Database
(http://web.ncifcrf.gov/rtp/gel/primerdb), qPrimerDepot
(http://primerdepot.nci.nih.gov) or Primer Bank (http://
pga.mgh.harvard.edu/primerbank/). The primers used are
Table III. A list of genes regulated by hyperglycemia and
Gene symbol Regulation Glucose, % TSP-1, % Man
RNU12 Down 23.7 19.8
DENND2C Down 7.0 6.0
SYT12 Up 12.0 12.0
OR4F15 Down 9.0 8.7
SEMA7A Down 4.0 4.0
OR3A3 Up 61.1% 36.0
C1QL1 Down 4.0 5.0
CCBL1 Down 2.0 2.7
aThe genes regulated by mannose are noted.listed in Table I. The genes of interest were TSP-1, TGF 2,HAS2,HES1, FOS,UGDH,NFAT5,PIK3CA,ROCK2, and
SOS1.
Statistical analysis. Microarray analysis was accom-
plished by Robust Multiarray Averaging (RMA) normaliza-
tion of CEL files in GeneSpring GX 10 software (Agilent
Technologies). Only probe sets with an expression value
20th percentile of all values in at least one sample were
used (threshold of 24,431 of 28,869 for all samples). A
one-way analysis of variance (ANOVA) was then used to
identify genes with differential expression in any of the
samples. The P value from this main effect ANOVA was
corrected using the Benjamini-Hochberg false discovery
Fig 1. Volcano plot shows microarray data obtained from 25 mM
glucose vs 5 mM glucose. Thirty genes were altered by 25 mM
glucose (3 experiments). The x-axis of these plots represents the
fold change in gene expression in a log2 format, thus any point0
represents a down-regulated gene. The y-axis is the –log10 of the P
value and all points in black are significant (P  .05).
mbospondin-1 (TSP-1) is presenteda
% Description
RNA, U12 small nuclear
DENN/MADD domain containing 2C
Synaptotagmin XII
Olfactory receptor, family 4F15
CD108
Olfactory receptor, family 3A3
Complement component 1
Cysteine conjugate- lyase; associated with nephrotoxicity
and neurotoxicitythro
nose,
5.9
9.0
6.7
2.5rate method (corrected FDR cutoff  0.05). Post hoc t
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cance set at P  .05. Gene group functions were analyzed
through the use of Ingenuity Pathway Assist (Ingenuity
Systems, www.ingenuity.com). The functional analysis
identified the biologic functions or diseases that were most
represented in the data set. Genes from the data set that met
the log2 (ratio) cutoff of 0.38 (30% change) and were
associated with biologic functions or diseases, or both, in
the Ingenuity Pathways Knowledge Base were considered
for the analysis.
RESULTS
Hyperglycemia induces altered gene expression in
VSMCs. Exposure of VSMCs to hyperglycemia resulted
in the altered expression of 30 genes that survived stringent
statistical criteria (Benjamini-Hochberg FDR cutoff 
0.05). This was a short-term exposure, and longer or
shorter intervals could yield different results. When the data
were filtered to analyze genes with expression changes
surpassing a magnitude of 0.38 (30% change) on a log2
(ratio) scale, analysis of canonical pathways (pathways that
have been well characterized from the literature by Ingenu-
Fig 2. Volcano plot shows microarray data obtained from
thrombospondin-1 (TSP-1) vs 5 mM glucose-treated vascular
smooth muscle cells. TSP-1 (3 experiments) altered 212 genes.
The x-axis of these plots represents the fold change in gene
expression in a log2 format; thus, any point 0 represents a
down-regulated gene. The y-axis is the –log10 of the P value and all
points in black are significant (P  .05). The three most up-
regulated genes were UGDH, TGF2, and HAS2.ity Systems) in the IPA software revealed only the NRF2-mediated oxidative stress response pathway was affected,
and this was verified by qrtPCR. In addition, gene network
analysis showed alteration of the gene network regulating
cellular development, lipid metabolism, and molecular
transport. Although microarray analysis did not show an
alteration in TSP-1, qrtPCR demonstrated a 67% increase
in TSP-1 messenger RNA (mRNA) in response to hyper-
glycemia.
TSP-1 up-regulates genes involved in atherosclero-
sis and diabetes. Examination of the 212 genes altered in
VSMCs by TSP-1 revealed that 10 genes known to be
up-regulated in atherosclerosis were indeed up-regulated by
TSP-1 (Table II). Three of these genes were up-regulated in
diabetic vascular cells (Table II). Of most interest is that the three
most up-regulated genes were uridine 5=-diphosphoglucose
(UDP-glucose) dehydrogenase (UGDH, 127%), transform-
ing growth factor -2 (TGF2, 116%), and hyaluronan
synthase 2 (HAS2, 113%). Quantitative rtPCR verified that
both TGF 2 and HAS2 were up-regulated by TSP-1, but
qrtPCR for UGDH did not show a difference from control.
These findings suggest a relationship with hyaluronic acid
synthesis.19,20
Genes commonly regulated by hyperglycemia and
TSP-1. Microarray analysis demonstrated that hypergly-
Fig 3. Volcano plot shows microarray data obtained from 25 mM
glucose  thrombospondin-1 (TSP-1) vs 5 mM glucose-treated
vascular smooth muscle cells. TSP-1 (3 experiments) altered 2822
genes. The x-axis of these plots represents the fold change in gene
expression in a log2 format; thus, any point 0 represents a
down-regulated gene. The y-axis is the –log10 of the P value, and
all points in black are significant (P  .05).cemia and TSP-1 regulated eight overlapping genes in a
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had a similar effect on four of these genes (Table III).
Interestingly, the hyperglycemia  TSP-1 group showed
no alteration of these genes.
The combination of hyperglycemia and TSP-1 up-
regulates genes not regulated by hyperglycemia or
TSP-1 alone. Volcano plots of the gene expression pat-
terns due to the various treatments are displayed in Figs 1,
2, and 3. The x-axis of these plots represents the fold
Fig 4. Canonical pathways affected by thrombospondi
ment of vascular smooth muscle cells as determined by In
30%, and only pathways that crossed a significance thre
canonical pathways. IGF-1, Insulin-like growth factor-1
factor .
Table IV. A listing of the canonical pathways altered by
thrombospondin-1 and confirmed by quantitative real-
time polymerase chain reaction with the genes used for
confirmation noted
Canonical pathway Gene symbol
Aryl hydrocarbon receptor signaling FOS, TGF 2
TGF- signaling FOS, TGF 2, SOS1
RAR activation TGF 2, PIK3CA
IGF-1 signaling FOS, SOS1
Cell cycle: G1/S checkpoint regulation TGF 2
IGF-1, Insulin-like growth factor 1; RAR, retinoic acid receptor; TGF-,
transforming growth factor-.change in gene expression in a log2 format, thus any point0 represents a down-regulated gene. The y-axis is the
log10 of the P value, and all points in black are significant
(P  .05). The patterns of genes altered by hyperglycemia
(Fig 1) and TSP-1 (Fig 2) were distinctly different, with
hyperglycemia altering 30 genes and TSP-1 altering 212
genes. Combined treatment of VSMCs with hyperglycemia
and TSP-1 caused a dramatic increase in gene alteration
compared with hyperglycemia or TSP-1 alone. Fig 3 dem-
onstrates that the combined treatment altered 2822 genes
compared with 30 genes for hyperglycemia (Fig 2) and 212
genes for TSP-1 (Fig 3). The osmotic control for this
experiment, 25 mM mannose TSP-1, altered the expres-
sion of 2107 genes, thus indicating that glucose (nonos-
motic effect) was responsible for the changes seen in 715
genes. For the three most up-regulated proteins by TSP-1
alone, the addition of glucose to TSP-1 treatment only
affected UDP-glucose dehydrogenase (127% for TSP-1
alone and 109% for TSP-1 25 mM glucose). Among the
genes up-regulated by TSP-1 25 mM glucose was UDP-
glucose ceramide glucosyltransferase, also known as glu-
cosylceramide synthase (311%).
Canonical pathways altered by TSP-1. Ingenuity
Pathway software analyzes the data set and compares the
information with well-characterized signaling pathways.
TSP-1) treatment compared with 5 mM glucose treat-
ity pathway analysis. Data were analyzed with a cutoff of
of P  .05 are displayed. TSP-1 treatment altered 13
R, retinoic acid receptor; TGF-, transforming growthn-1 (
genu
shold
; RATSP-1 treatment of VSMCs for 6 hours resulted in alter-
JOURNAL OF VASCULAR SURGERY
Volume 51, Number 5 Maier et al 1243Fig 5. Canonical pathways affected by 25 mM glucose thrombospondin-1 (TSP-1) treatment compared with 5 mM
glucose treatment of vascular smooth muscle cells as determined by Ingenuity pathway analysis. Data were analyzed
with a cutoff of 30%, and only pathways that crossed a significance threshold of P .05 are displayed. Treatment with
25 mM glucose  TSP-1 altered 53 canonical pathways. EGF, Endothelial growth factor; ERK, extracellular
signal-regulated kinase; IGF-1, insulin-like growth factor 1; IL-10, interleukin-10; IL-6, interleukin 6; MAPK,
mitogen-activated protein kinase; PDGF, platelet-derived growth factor; PPAR, peroxisome proliferator-activated
receptor; RAR, retinoic acid receptor; TGF-, transforming growth factor; VDR/RXR, vitamin D3 receptor/
retinoid-X receptor; BMP, bone morphogenetic protein; SAPK/JNK, stress-activated protein kinase/c-Jun NH2-
terminal kinase; TRK, neurotrophin receptor; TR, thyroid hormone receptor; AKT, protein kinase b; PI3K, phospha-
tidylinositol 3 kinase; LXR, liver X receptor; IL-8, interleukin 8; FGF, fibroblast growth factor; IL-10, interleukin 10;
PTEN, phosphatase and tensin homolog.
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are most relevant to vascular disease are the TGF signaling
pathway and the insulin-like growth factor 1 (IGF-1) path-
ways (Fig 4). Several of these pathways were validated with
qrtPCR (Table IV).
Canonical pathways altered by hyperglycemia 
TSP-1. Treatment of VSMCs with hyperglycemia 
TSP-1 resulted in alterations of 53 canonical pathways.
Several of the altered pathways are relevant to vascular
disease in this data set. These include acute-phase reaction
signaling, extracellular signal-regulated kinase (ERK) sig-
naling, TGF signaling, stress-activated protein kinase
(SAPK) signaling, phosphoinositide-3 kinase (PI3K) sig-
naling, regulation of actin-based motility by Rho signaling,
vascular endothelial growth factor (VEGF) signaling, platelet-
derived growth factor (PDGF) signaling, interleukin-6
(IL-6) signaling, fibroblast growth factor (FGF) signaling,
and the insulin-like growth factor 1 (IGF-1) pathway (Fig
5). Several of these pathways were validated with qrtPCR
(Table V).
DISCUSSION
The incidence of type 2 diabetes is on the rise in the
United States.1 A major complication of diabetes is cardio-
vascular disease, specifically atherosclerosis.2 TSP-1 is a
matricellular glycoprotein that is involved in the progres-
Table V. A listing of the canonical pathways altered by
hyperglycemia and thrombospondin-1 and confirmed by
quantitative real-time polymerase chain reaction with the
genes used for confirmation noted
Canonical pathway Gene symbol
Glucocorticoid receptor signaling FOS, NFAT5, PIK3CA
RAR activation TGF 2, PIK3CA
Acute phase response signaling FOS, PIK3CA
ERK/MAPK signaling FOS, PIK3CA
TGF- signaling FOS, TGF 2
EGF signaling FOS, PIK3CA
Aryl hydrocarbon receptor signaling FOS, TGF 2
Neurotrophin/Trk signaling FOS, PIK3CA
Hepatic fibrosis/hepatic stellate cell
activation TGF 2
Wnt/-catenin signaling TGF 2, PIK3CA
Tight junction signaling FOS, TGFB2
IL-6 signaling FOS
PDGF signaling FOS, PIK3CA
Notch signaling HES1
IL-10 signaling FOS
Chemokine signaling FOS, Rock2
VDR/RXR activation HES1, TGFB2
Cell cycle: G1/S checkpoint regulation TGFB2
IGF-1 signaling FOS, PIIK3CA
PPAR signaling FOS
EGF, Endothelial growth factor; ERK, extracellular signal-regulated kinase;
IGF-1, insulin-like growth factor 1; IL-10, interleukin-10; IL-6, interleukin
6;MAPK,mitogen-activated protein kinase; PDGF, platelet-derived growth
factor; PPAR, peroxisome proliferator-activated receptor; RAR, retinoic
acid receptor; TGF-, transforming growth factor-; VDR/RXR, vitamin
D3 receptor/retinoid-X receptor.sion of atherosclerosis, is up-regulated by hyperglycemia inVSMCs, and is increased in the vasculature of animal mod-
els of type 2 diabetes.7,16,17
Few studies have examined the effect of hyperglycemia
or TSP-1 on VSMC gene expression. The microarray anal-
yses presented show that hyperglycemia alone alters rela-
tively few genes in VSMCs during the 6-hour incubation
period, while TSP-1 induced alteration of many more
genes. Surprisingly, the combination of hyperglycemia and
TSP-1 for the same incubation period dramatically in-
creased the number of genes altered that cannot be ex-
plained by a simple additive effect of the two treatments.
The 10 most up-regulated and 10 most down-regulated
genes for each condition are presented in Table VI. Hyper-
glycemia alone did not cause the down-regulation of any
genes.
Previous work showed that hyperglycemia induces
TSP-1 mRNA in VSMCs after 24 hours, which is consistent
with our data.16 We found up-regulation of TSP-1 mRNA
after 6 hours of VSMC treatment with TSP-1, hyperglyce-
mia, or both. Interestingly, this effect was not seen in the
microarray data but only in the qrtPCR studies. Two pos-
sible explanations exist for this observation:
First, qrtPCR is well established as a more sensitive tech-
nique than microarray. This increased sensitivity is par-
ticularly true if the array data are normalized using the
RMA algorithm developed by Terrence Speed and
colleagues. Although this algorithm is vastly superior to
others in controlling for type I error rates (false-positive
changes in expression), it is more prone to higher rates
of type II errors (false-negatives) than other methods
and generally underestimates the magnitude of changes
seen by qrtPCR.
Second, although the exon level probes used in the ST
Gene microarray interrogate every exon of TSP-1, the
qrtPCR data were derived from the quantification of
differences in expression of a very small fragment of the
cDNA. It is possible that the alternative splicing of the
TSP-1 transcript in response to TSP-1, hyperglycemia,
or both may have influenced the qrtPCR finding.
Patients with diabetes are at a greater risk for athero-
sclerosis.2 Previous studies have shown that the proathero-
sclerotic matricellular protein, TSP-1, is up-regulated in the
tissues of animal models of type 2 diabetes.17 Further,
studies from our laboratory and others have demonstrated
a role for TSP-1 in the cellular events that contribute to
atherosclerosis.5,6,9-11,18,21 This current study used mi-
croarray analysis to examine the role of TSP-1 on gene
expression in VSMCs. TSP-1 affected 212 genes. The three
most up-regulated genes in the TSP-1 group were UGDH
(127%), TGF 2 (116%), and HAS2 (113%). These three
genes are intimately involved in hyaluronic acid synthe-
sis.19,20 Because hyaluronic acid is known to cause VSMC
migration and is expressed in atherosclerotic plaque, this
pathway may represent a key step in the role of TSP-1 in the
development of vascular disease.7,20,22
The fact that qrtPCR did not indicate that UGDH was
up-regulated by TSP-1 is perplexing. It is possible that
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down-regulated genes in the hyperglycemia group)
Treatment with hyperglycemia Treatment with thrombospondin-1
Treatment with hyperglycemia 
thrombospondin-1
Gene Description % Gene Description % Gene Description %
Increased
OR3A3 Olfactory receptor,
family 3,
subfamily A,
member 3
55.7 UGDH UDP-glucose
dehydrogenase
130.1 UGCG UDP-glucose
ceramide
glucosyltransferase
311.5
DNAJB14 DnaJ (Hsp40)
homolog,
subfamily B,
member 14
36.3 HAS2 Hyaluronan
synthase 2
118.9 CPEB4 Cytoplasmic
polyadenylation
element binding
protein 4
281.8
RSL24D1 Ribosomal L24
domain
containing 1
33.5 TGF2 Transforming
growth factor 2
112.6 ARSI Arylsulfatase family,
member I
210.2
FAM126B Family with
sequence
similarity 126,
member B
32.4 SLC2A1 Solute carrier family
2 (facilitated
glucose
transporter)
106.2 JMJD1C Jumonji domain
containing 1C
199.4
KRTAP4-3 Keratin-associated
protein 4-3
29.9 NOP5/NOP58
NOP58
Ribonucleoprotein
homolog (yeast)
93.1 FAP Fibroblast activation
protein, alpha
198.6
RNF160 Ring finger protein
160
23.8 ARSI Arylsulfatase family,
member I
89.5 PELI1 Pellino homolog 1
(Drosophila)
184.0
LIX1L Lix1 homolog
(mouse)-like
22.1 IVNS1ABP Influenza virus
NS1A binding
protein
77.8 MIRN21 MicroRNA 21 181.7
ND6 NADH
dehydrogenase,
subunit 6
(complex I)
18.9 INHA Inhibin A 75.0 ROCK2 Rho-associated,
coiled-coil
containing protein
kinase 2
176.6
SSB Sjogren syndrome
antigen B
(autoantigen La)
18.7 TIMP3 TIMP
metallopeptidase
inhibitor 3
74.6 FOSB FBJ murine
osteosarcoma viral
oncogene homolog
B
161.2
C15ORF51 Chromosome 15
open reading
frame 51
18.6 BXDC2 Brix domain
containing 2
71.1 BAT1 HLA-B associated
transcript 1
154.2
Decreased
NR2F1 Nuclear receptor
subfamily 2, group
F, member 1
32.5 IL1 Interleukin 1 461.4
ARR1 Arrestin 1 35.6 PTGS2 Prostaglandin-
endoperoxide
synthase 2
481.2
DAPK1 Death-associated
protein kinase 1
41.6 C1S Complement
component 1, s
subcomponent
485.6
LDB1 LIM domain
binding 1
42.4 MALAT1 Metastasis-associated
lung
adenocarcinoma
transcript 1
500.4
KLHL24 Kelch-like 24
(Drosophila)
43.0 P4H Prolyl 4-hydroxylase
 polypeptide
535.5
ARID5B AT rich interactive
domain 5B
(MRF1-like)
43.8 IL8 Interleukin 8 573.7
YPEL3 Yippee-like 3
(Drosophila)
61.9 IL6 Interleukin 6 633.6
NOVA1 Neuro-oncological
ventral antigen 1
76.4 RPL5 Ribosomal protein L5 829.9
MEIS1 Meis homeobox 1 83.7 MMP1 Matrix metallopeptidase
1
1023.6NFIB Nuclear factor I/B 86.6 2M -2-microglobulin 1517.8
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is declining, resulting in variability of our replicates. A
possible explanation for not detecting an increase in
UGDH with qrtPCR is that while the exon level probes
used in the ST Gene microarray interrogate every exon of
UGDH, the qrtPCR data were derived from the quantifi-
cation of differences in expression of a very small fragment
of the cDNA. It is possible that the alternative splicing of
the UGDH transcript in response to TSP-1 may have
influenced the qrtPCR finding. Future studies will investi-
gate UGDH as well as HAS2 and TGF 2 at the protein
level to determine their role in TSP-1 signaling.
The specific role that hyaluronic acid plays in TSP-1
signal transduction remains to be determined. Further,
although several studies have shown a role for TSP-1 in the
activation of TGF1, few studies have examined any rela-
tionship between TSP-1 and TGF2.3,14,23-28 There have
been no studies regarding the relationship of these two
proteins in VSMCs. However, TGF2 has been shown to
induce TSP-1 mRNA in cultured astrocytes and trabecular
meshwork cells, and expression of both TSP-1 and TGF2
has been found in glioma cells.29-31 Interestingly, the ad-
dition of a hyperglycemic environment did not increase
TGF 2 or HAS2 but did induce a slight decrease in
UGDH expression.
Treatment of VSMCs with hyperglycemia  TSP-1
caused an order of magnitude increase in altered gene
expression. This result cannot be explained as an additive
effect of the changes seen with hyperglycemia or TSP-1
alone. Indeed, although glucose altered 30 genes and
TSP-1 altered 212 genes, for a total of 236 genes (there
were 8 overlapping genes), when the treatments were com-
bined, the result was 2822 genes altered. When the osmotic
control treatment, 25 mM mannoseTSP-1, is subtracted
from this result, 715 genes remain that were altered due to
the hyperglycemia  TSP-1 treatment comprising both
overlapping and nonoverlapping genes.
Of further interest is that a gene involved in glucosyl-
ceramide glycosphingolipid synthesis, UDP-glucose cer-
amide glucosyltransferase (also known as glucosylceramide
synthase), was up-regulated 311%, which was not altered by
hyperglycemia or TSP-1 alone.32 Glycosphingolipids are
under scrutiny for their role in vascular disease because
they have been found to be up-regulated in cells isolated
from atherosclerotic plaque.33-36 Specifically, many spe-
cies of ceramide-derived glycosphingolipids, including
glucosylceramide, have been identified in these tis-
sues.33-36 Therefore, these glycosphingolipids may rep-
resent a novel pathway by which TSP-1 expression in the
presence of hyperglycemia may enhance the development
of atherosclerotic lesions.
Analysis of the canonical pathways affected by hyper-
glycemia showed that one pathway was altered, whereas
TSP-1 treatment altered 13 pathways. Two of these path-
ways, TGF signaling and the IGF-1 pathway, are known
to be involved in processes related to vascular disease.37-39
Interestingly, the combination of hyperglycemia and
TSP-1 altered 53 pathways. Of these pathways, 12 areknown to be involved in the progression of vascular disease.
Thus, this analysis reinforces the concept that hyperglyce-
mia and TSP-1 interact in a complex nonadditive manner
on VSMCs. The qrtPCR data do not address the effect of
the treatments on the regulation of these pathways, which
often occurs through phosphorylation. Rather, the qrtPCR
data represent the effect of these treatments on gene ex-
pression related to these canonical pathways.
CONCLUSION
The present study examined the effect of TSP-1 and
hyperglycemia  TSP-1 on gene expression in VSMCs
compared with the effect of normoglycemia. The data
indicate that TSP-1 alters the expression of many genes
having a significant effect on several signaling pathways.
However, the surprising finding in this study is that the
combination of hyperglycemia and TSP-1 altered the ex-
pression of 10 times as many genes as TSP-1 alone and
affected 4 times as many canonical pathways. Future studies
will be needed to fully understand this complex relation-
ship.
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